Clinical Trial Update: A Study of ASP2215 (Gilteritinib) Combined With Atezolizumab in Patients With Relapsed or Treatment Refractory FMS-like Tyrosine Kinase (FLT3) Mutated Acute Myeloid Leukemia (AML) [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating the combination of gilteritinib and atezolizumab in relapsed or FLT3-mutated acute myeloid leukemia. The study is completed and resul…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Acute Myeloid Leukemia with Flt3 Mutation

Drugs mentioned

• Atezolizumab (atezolizumab)
• Gilteritinib (ASP2215) (gilteritinib)

Snippet

Sponsor: Astellas Pharma Global Development, Inc. | Conditions: Acute Myeloid Leukemia (AML), Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) Mutation | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2022-06-24